# Enliven Therapeutics

Source: https://onco.cc/companies/enliven-therapeutics/  
OnCo record `enliven-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Enliven Therapeutics designs cleaner versions of cancer pills that already work. Its lead drug targets the BCR-ABL protein in chronic myeloid leukaemia and a second drug targets mutated HER2 in lung cancer.

## Summary

Enliven Therapeutics is a Boulder, Colorado clinical-stage precision oncology company developing next-generation small molecule kinase inhibitors intended to improve tolerability, combinability and resistance coverage. ELVN-001 is a potent, highly selective BCR-ABL inhibitor that binds a distinctive folded-in P-loop conformation of ABL1 and is in clinical development for chronic myeloid leukaemia (CML). ELVN-002 is a selective, irreversible HER2 inhibitor with activity against HER2 mutations including exon 20 insertions in non-small cell lung cancer, in phase 1. Enliven became a Nasdaq company in February 2023 by merging with Imara Inc., closing a concurrent 165 million US dollar private placement co-led by Fairmount and Venrock Healthcare Capital Partners; shares trade as ELVN.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Boulder, CO
- Type: biotech
- Website: https://www.enliventherapeutics.com/
- Ticker: ELVN

## Notes

- Chronic myeloid leukaemia has no id in the cancer list so is not tagged. Pre-merger venture rounds and founding year not sourced.

## Sources

- Official website: https://www.enliventherapeutics.com/
- Pipeline: https://www.enliventherapeutics.com/pipeline/
- Merger closing and private placement (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/d464771dex991.htm

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [5AM Ventures](https://onco.cc/companies/5am-ventures/), [Frazier Life Sciences](https://onco.cc/companies/frazier-life-sciences/), [RA Capital Management](https://onco.cc/companies/ra-capital/), [Venrock](https://onco.cc/companies/venrock/)

---
JSON: https://onco.cc/api/v1/entities/enliven-therapeutics.json